Skip to main
AUTL

Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics (AUTL) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Autolus Therapeutics is expected to experience significant growth in the next few years, primarily driven by the growing demand and access for Aucatyzl in both the US and UK markets. The company's clinical-stage pipeline also shows promising potential for the treatment of cancer and autoimmune indications. Additionally, the company's strong financial performance, with $26.2M in revenue generated in 1Q26 and expected revenue of $120-135M in 2026, reveals its capability to drive continued growth. The potential of AUTO-8 in AL amyloidosis and obe-cel in progressive MS, with early data expected in 2026, serves as short-term catalysts, and the company's focus on safety and ease of use of Aucatzyl, as highlighted by KOLs, positions the company for long-term success in the competitive market of CAR-T therapies.

Bears say

Autolus Therapeutics is a platform technology company with a diverse pipeline, but risks to the achievement of our $10 price target include safety concerns with clinical programs, potential for lower than expected efficacy, and stiff competition in the market. Additionally, significant capital will be needed through 2040, and the company's cash runway only extends to 2027, posing a financial risk. The company's success in the pediatric relapse ALL market may provide some opportunities, but risks such as regulatory concerns and risks related to intellectual property also remain.

Autolus Therapeutics (AUTL) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Autolus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Autolus Therapeutics (AUTL) Forecast

Analysts have given Autolus Therapeutics (AUTL) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Autolus Therapeutics (AUTL) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Autolus Therapeutics (AUTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.